(Reuters) -Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
Ullem, who joined the company in 2014, helped guide its expansion in structural heart therapies and shift toward underserved markets. The company said the planned transition will ensure continuity.
The announcement came alongside the company’s third-quarter results, which beat Wall Street estimates. Sales rose 14.7% to $1.55 billion, driven by strong demand across its transcatheter valve therapies, compared with estimates of $1.49 billion according to data compiled by LSEG.
Shares of the company were up about 3% in after-market trading.
The company also raised its full-year sales and profit forecasts.
(Reporting by Anshi Sancheti in Bengaluru; Editing by Alan Barona)
Brought to you by www.srnnews.com
